Paratek Pharma’s Phase 3 NUZYRA trial results published in The Lancet Infectious Diseases

The results of Paratek Pharmaceuticals’ (NASDAQ:PRTK) Phase 3 trial of NUZYRA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) have been published in the peer-reviewed journal, The Lancet Infectious Diseases.

NUZYRA is a once-daily tetracycline that is FDA-approved for the treatment of adults with community-acquired bacterial pneumonia and ABSSSI.

The trial, called OASIS-2, evaluated oral-only NUZYRA compared to twice-daily oral-only linezolid in 735 adults with ABSSSI. NUZYRA met the FDA-specified primary endpoint of statistical non-inferiority compared to linezolid at 48 to 72 hours after the first dose. The early clinical response rate for NUZYRA was 87.5% compared with 82.5% for linezolid.

“Results from OASIS-2 demonstrate that once-daily, oral-only NUZYRA is an effective, well-tolerated monotherapy across multiple types of skin infections and bacterial pathogens – including resistant pathogens such as MRSA,” Dr. Evan Loh, CEO of Paratek, said in a statement.

The research article, entitled “Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial,” is available here.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.